Payment overview · 2025
General Payments
$2,244.56
90 reported records · 23 companies
Healthcare provider profile · identity verified
William Eaves, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SHREVEPORT, LA · NPI 1801861240
Verified facts
What the public records show
CMS Open Payments records show William Eaves, MD received $2,244.56 in general payments during 2025 across 90 reported records.
Boston Scientific Corporation accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $418.40 | 18.6% | 12 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $290.09 | 12.9% | 18 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $237.50 | 10.6% | 10 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $236.71 | 10.6% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $229.13 | 10.2% | 11 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $153.58 | 6.8% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $106.65 | 4.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $89.44 | 4.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.93 | 2.3% | 3 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $43.90 | 2.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.42 | 1.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $40.26 | 1.8% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $38.03 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.35 | 1.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.31 | 1.7% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $35.71 | 1.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.19 | 1.5% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $28.65 | 1.3% | 2 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $21.93 | 1.0% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $20.90 | 0.9% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $19.66 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.58 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.24 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,244.56 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $236.71 | 7 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $156.10 | 3 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $155.46 | 3 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $153.58 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $128.58 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $128.58 | 4 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $106.65 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $106.65 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $89.44 | 5 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $84.34 | 4 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $62.61 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.93 | 3 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $43.90 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $41.42 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $40.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.19 | 3 | 2025 |
Source payment records
|
|||||
| OptiCross 35 Normalized: opticross 35 |
Device | Boston Scientific Corporation | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| GLIDEWIRE Normalized: glidewire |
Device | Terumo Medical Corporation | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 354 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
142 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
354 | 68 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
354 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 408 | 111 |
| Eliquis | Apixaban | 354 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 336 | 96 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 260 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 64 |
| Entresto | Sacubitril/Valsartan | 184 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 158 | 42 |
| Losartan Potassium | Losartan Potassium | 158 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 43 |
| Carvedilol | Carvedilol | 143 | 40 |
| Brilinta | Ticagrelor | 142 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 29 |
| Propafenone Hcl | Propafenone Hcl | 100 | 22 |
| Repatha Sureclick | Evolocumab | 99 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 20 |
| Furosemide | Furosemide | 86 | 27 |
| Jardiance | Empagliflozin | 82 | 14 |
| Lisinopril | Lisinopril | 74 | 25 |
| Nifedipine Er | Nifedipine | 74 | 18 |
| Ezetimibe | Ezetimibe | 61 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 48 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Cilostazol | Cilostazol | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Ozempic | Semaglutide | 30 | 11 |
| Simvastatin | Simvastatin | 30 | 11 |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 18 |
| Prasugrel Hcl | Prasugrel Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,244.56 · 90 records | Boston Scientific Corporation | ARTIX MT, Assure WCD, BodyGuardian, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, ECC Solutions, ELIQUIS, ELUVIA, ENDOCROSS Device, FLOWTRIEVER CATHETER, S, GLIDEWIRE, GORE VIABAHN Endoprosthesis with Heparin, General - Vascular Intervention, INSPIRE, JARDIANCE, JETSTREAM SC, Kerendia, LOKELMA, LifeVest, MCOT, METACROSS OTW, OptiCross 35, Paradise Ultrasound Renal Denervation System, Ranger, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, VERQUVO, WatchPATONE, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error